- E-postingunn.stefansson@uib.no
- BesøksadresseHaukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst5009 Bergen
- PostadressePostboks 78045020 Bergen
Vitenskapelig artikkel
- (2024). Age-related phenotypes in breast cancer: A population-based study. International Journal of Cancer.
- (2023). Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas. Cancer Medicine. 14183-14195.
- (2023). Endometrial Pipelle Biopsy Computer-Aided Diagnosis: A Feasibility Study. Modern Pathology. 9 sider.
- (2022). Neurogenesis and angiogenesis are associated features of aggressive breast cancer . bioRxiv.
- (2022). MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer. Insight into Imaging. 1-12.
- (2021). Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine. 1-14.
- (2021). Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Scientific Reports. 1-11.
- (2020). Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups. Scientific Reports. 14 sider.
- (2020). Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
- (2019). Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 1-11.
- (2018). High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
- (2017). Type of vascular invasion in association with progress of endometrial cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1084-1091.
- (2017). Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
- (2017). In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
- (2017). HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
- (2017). Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Scientific Reports. 1-12.
- (2017). Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. Cancer Immunology and Immunotherapy. 1463-1471.
- (2016). Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival. Journal of Clinical Pathology. 313-319.
- (2016). The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
- (2016). QSOX1 expression is associated with aggressive tumor features and reduced survival in breast carcinomas. Modern Pathology. 1485-1491.
- (2016). Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
- (2015). Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
- (2015). Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer. 459-466.
- (2015). Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
- (2015). Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
- (2015). ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
- (2014). Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
- (2014). High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
- (2014). Evaluation of Ki67 expression across distinct categories of breast cancer specimens: A Population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLOS ONE.
- (2014). Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
- (2014). An 18-Gene signature for vascular invasion is associated with aggressive features and reduced survival in breast cancer. PLOS ONE.
- (2013). Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
- (2013). Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 sider.
- (2013). Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer. 3431-3441.
- (2013). High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
- (2013). Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. Diagnostic Pathology.
- (2013). Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
- (2012). Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Research and Treatment. 501-510.
- (2012). Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast. 1-7.
- (2012). Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
- (2012). Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 7 sider.
- (2011). Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Research and Treatment. 1063-1071.
- (2011). Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. Clinical Cancer Research. 3368-3377.
- (2011). High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
- (2011). Gene Expression Patterns Related to Vascular Invasion and Aggressive Features in Endometrial Cancer. American Journal of Pathology. 861-871.
- (2011). Evolution in endometrial cancer evidence from an immunohistochemical study. International Journal of Gynecological Cancer. 316-322.
- (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
- (2009). Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecologic Oncology. 491-495.
- (2009). Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
- (2009). Importance of tumour cell invasion in blood and lymphatic vasculature among patients with endometrial carcinoma. Histopathology. 174-183.
- (2009). Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. American Journal of Obstetrics and Gynecology. 603-607.
- (2008). Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
- (2008). HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 307-316.
- (2008). Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 8713-8717.
- (2006). Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Research. 3303-3309.
- (2006). Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
- (2006). Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. International Journal of Cancer. 1227-1233.
- (2006). Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research. 1168-1174.
- (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
- (2005). Low frequency of BRAF and CDKN2A mutations in endometrial cancer. International Journal of Cancer. 930-934.
- (2005). A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiology, Biomarkers and Prevention. 1108-1112.
- (2004). The prognostic implication of the basal-like (cyclin E-high/p27(low)/p53(+)/glomeruloid-microvascular-proliferation(+)) phenotype of BRCA1-related breast cancer. Cancer Research. 830-835.
- (2004). Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology. 1615-1623.
- (2004). Prognostic impact of histological grade and vascular invasion compared with tumor cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 472-479.
- (2004). Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. Journal of Clinical Oncology. 1242-1252.
- (2004). Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
- (2003). Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1011-1018.
- (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
- (2002). Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research. 138-43.
- (2002). Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2185-91.
Leserinnlegg
- (2010). Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 641-646.
Doktorgradsavhandling
- (2005). Biologic and prognostic markers of endometrial carcinoma.
Sammendrag/abstract
- (2013). Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
- (2013). Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
- (2012). Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
- (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
- (2011). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
- (2010). Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 248-248.
Poster
- (2009). Stathmin is superior to AKT and Phospho-AKT staining to detect PI3Kinase activation and aggressive endometrial cancer.
- (2007). Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
- (2007). Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
- (2006). Gene expression profiles identify an aggressive phenotype in endometrial carcinoma.